推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 11月10日晚間公告，公司擬在甘肅漳縣的金鐘鎮(zhèn)和大草灘鄉(xiāng)投資1023.9萬(wàn)元，建設(shè)募投項(xiàng)目當(dāng)歸藥源GAP種植基地1萬(wàn)畝。
此前于2005年，在甘肅省經(jīng)貿(mào)委的支持下，公司當(dāng)歸藥源基地建設(shè)項(xiàng)目正式立項(xiàng)，并獲得國(guó)家中藥材生產(chǎn)扶持項(xiàng)目資金100萬(wàn)元。項(xiàng)目于2005年6月申報(bào)，2005年9月國(guó)家經(jīng)貿(mào)委批復(fù)實(shí)施，2007年12月結(jié)束。
“中藥材扶持”項(xiàng)目總投資為100萬(wàn)元，在漳縣金鐘鎮(zhèn)大車(chē)廠村建立1000畝當(dāng)歸藥源基地，因此此次擬種植面積與前述項(xiàng)目種植面積基本匹配。佛慈制藥表示，通過(guò)此次募投項(xiàng)目，公司將投資完善基地的組織運(yùn)營(yíng)機(jī)構(gòu)和生產(chǎn)經(jīng)營(yíng)配套設(shè)施，進(jìn)一步轉(zhuǎn)化基地現(xiàn)有科研技術(shù)成果，擴(kuò)大基地生產(chǎn)規(guī)模，建立萬(wàn)畝當(dāng)歸藥源基地。
